Cognition Therapeutics Inc (NASDAQ: CGTX) on Monday, plunged -5.39% from the previous trading day, before settling in for the closing price of $0.45. Within the past 52 weeks, CGTX’s price has moved between $0.34 and $2.95.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company achieved an average annual earnings per share of 4.46%. With a float of $33.67 million, this company’s outstanding shares have now reached $40.81 million.
Let’s determine the extent of company efficiency that accounts for 28 employees. In terms of profitability, gross margin is 48.66%, operating margin of -15707.53%, and the pretax margin is -9212.37%.
Cognition Therapeutics Inc (CGTX) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Cognition Therapeutics Inc is 18.96%, while institutional ownership is 12.30%. The most recent insider transaction that took place on Jan 31 ’25, was worth 30,001. In this transaction CEO & President of this company bought 38,851 shares at a rate of $0.77, taking the stock ownership to the 38,851 shares. Before that another transaction happened on Mar 14 ’24, when Company’s CEO & President bought 5,700 for $1.75, making the entire transaction worth $9,975. This insider now owns 291,345 shares in total.
Cognition Therapeutics Inc (CGTX) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.13 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 4.46% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 9.38% during the next five years compared to -21.09% drop over the previous five years of trading.
Cognition Therapeutics Inc (NASDAQ: CGTX) Trading Performance Indicators
Cognition Therapeutics Inc (CGTX) is currently performing well based on its current performance indicators. A quick ratio of 2.11 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.96, a number that is poised to hit -0.17 in the next quarter and is forecasted to reach -0.61 in one year’s time.
Technical Analysis of Cognition Therapeutics Inc (CGTX)
Looking closely at Cognition Therapeutics Inc (NASDAQ: CGTX), its last 5-days average volume was 9.34 million, which is a jump from its year-to-date volume of 2.08 million. As of the previous 9 days, the stock’s Stochastic %D was 8.04%. Additionally, its Average True Range was 0.06.
During the past 100 days, Cognition Therapeutics Inc’s (CGTX) raw stochastic average was set at 9.47%, which indicates a significant increase from 0.00% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 57.44% in the past 14 days, which was lower than the 103.05% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.6634, while its 200-day Moving Average is $0.9473. However, in the short run, Cognition Therapeutics Inc’s stock first resistance to watch stands at $0.4567. Second resistance stands at $0.4833. The third major resistance level sits at $0.4967. If the price goes on to break the first support level at $0.4167, it is likely to go to the next support level at $0.4033. Now, if the price goes above the second support level, the third support stands at $0.3767.
Cognition Therapeutics Inc (NASDAQ: CGTX) Key Stats
Market capitalization of the company is 17.88 million based on 41,548K outstanding shares. Right now, sales total 0 K and income totals -25,790 K. The company made 0 K in profit during its latest quarter, and -9,940 K in sales during its previous quarter.
